Turnstone Biologics Corp

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Turnstone Biologics Corp. operates as a clinical stage biotechnology company. It engages in the business of developing and commercializing therapeutics. The company is focused on developing new medicines to treat and cure patients with solid tumors. Turnstone Biologics was founded in 2015 and is headquartered in La Jolla, CA.

Clinical-stage biotechnology company Turnstone Biologics Corp has filed for an $86 million IPO on the Nasdaq. The San Diego-based firm, which is developing next-generation immunotherapies to treat solid tumors, plans to trade on the US exchange under the ticker symbol ‘TSBX.

Turnstone Biologics files for $86M IPO: will more biotech firms follow?

News for Turnstone Biologics Corp Stock (TSBX)